Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Redx Pharma secures $36M in Series A financing led by Abingworth, backed by British Business Bank and Redmile. The funding will support Fibrx's operations and its lead program RXC008.
PRIVATEAug 15, 2026•about 3 hours ago
Amount Raised
$36 Million
Round Type
Series A
United KingdomBiotechnologyHealth CareTherapeuticsInvestors
RedmileBritish Business BankAbingworth
Description
Redx Pharma has entered a $36 million Series A financing round led by Abingworth, with British Business Bank and Redmile participating. The financing is expected to close soon, subject to shareholder approval. This funding is part of a larger transaction that will enable Redx to focus on developing RXC008 for fibrotic disease. The combined cash balance is projected to fund operations through 2029.
Don't miss Redx Pharma's next move
Get an email the moment Redx Pharma raises, hires an exec, or expands — usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
1 contactVerified contactsJames M., Chief Operating Officer hidden
Funding Insights
Based on industry dataTypical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech